Albemarle Makes Final Proposal for the Acquisition of Liontown

Australian lithium miner Liontown announced that it has received a revised conditional and non-binding indicative proposal from Albemarle to acquire all of the ordinary shares outstanding in Liontown for A$3.00 in cash per share via scheme of arrangement. The revised proposal values Liontown at A$6.6 billion ($4.3 billion) on an equity value basis.

The new cash offer of A$3 per share represents a 14.5% premium to Liontown's last closing price of A$2.62 on Sept. 1 and is 20% higher than Albemarle's offer of A$2.50 per share, which the company rejected as too low in late March.

Albemarle said that the revised indicative proposal is its best and final proposal, in the absence of a superior proposal.

Liontown confirmed that, subject to entry into a mutually acceptable non-disclosure and exclusivity agreement, its board intends to unanimously recommend that shareholders vote in favor of the new offer in the absence of a better offer and after an independent expert has reviewed the deal.

Source: Liontown Resources
Source: Liontown Resources

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.